MedImmune has joined the NIH’s Centers for Accelerated Innovations (NCAI) program as its first biopharma corporate partner.
The global biologics research and development arm of AstraZeneca said it will team up with NCAI awardees and help shape the program’s strategic direction. MedImmune said it may also review prospective NCAI technologies in collaboration with the awardees, and provide feedback regarding their commercial potential and early-stage development.
{iframe}http://www.genengnews.com/gen-news-highlights/medimmune-joins-nih-s-centers-for-accelerated-innovations/81250940/{/iframe}